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Summary
Autosomal dominant polycystic kidney disease (ADPKD) is characterized by the development 
and progressive enlargement of cysts in the kidneys. The diagnosis of ADPKD is usually deter-
mined by criteria of renal ultrasound imaging of the development and number of cysts. However, 
in atypical cystic disease, for the recognition of ADPKD, DNA-based assays may be required.
In the present study PCR amplified fragments of the PKD1 gene (covering exons 15 and 43- 44) 
from genomic DNA of 134 Lower Silesia patients were analyzed for mutations and polymor-
phisms. Among them, the clinical significance of different PKD1 mutations was investigated 
in 81 persons.
Eight new, previously undescribed, and 2 recurrent mutations were discovered. The presence of 
3 known polymorphisms was confirmed. Seven of the 8 new discovered mutations were hete-
rozygous. 
The results of the present study demonstrated that the frequency of genetic abnormalities in the 
analyzed fragments of the PKD1 gene in the Lower Silesian population is smaller than previo-
usly reported. Moreover, we could not detect deletions and insertions, which are often present is 
these regions of the PKD1 gene, which may be due to the limited number of screened patients. 
We conclude that none of the discovered changes in the PKD1 gene had any effect on clinical 
phenotype of the disease.
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Abbreviations:  ACE –  enzym konwertujący angiotensynę, ADPKD – autosomalna dominująca postać zwyrod-
nienia torbielowatego nerek, dNTP– deoksynukleozydo-5’-trifosforan, ESRD – schyłkowa niewy-
dolność nerek, MSSCP – wielotemperaturowy polimorfizm konformacji pojedynczej nici DNA, 
SSCP – polimorfizm konformacji pojedynczej nici DNA, PCR  – reakcja łańcuchowa polimerazy, 
PKD1 – gen odpowiedzialny za zwyrodnienie torbielowate nerek 1, PKD2– gen odpowiedzialny 
za zwyrodnienie torbielowate nerek 2.
Streszczenie
Autosomalna, dominująca postać zwyrodnienia torbielowatego nerek (ADPKD) jest jedną z 
najczęstszych schorzeń genetycznych, charakteryzująca się rozwojem niezliczonej liczby, różnej 
wielkości torbieli w korze i rdzeniu nerek. Rozpoznanie choroby opiera się głównie na pod-
stawie badań obrazowych, przede wszystkim badaniu ultrasonograficznym jamy brzusznej. W 
przypadkach nietypowych pomocne  mogą być badania genetyczne.
W pracy analizowano mutacje i polimorfizmy fragmentów genu PKD1 obejmujących eksony 
43-44 oraz ekson 15. Fragmenty  namnożono za pomocą metody PCR z genomowego DNA 
134 dolnośląskich pacjentów. U 81 osób analizowano  kliniczne znaczenie różnych mutacji w 
genie PKD1.  
Wykryto osiem nowych, poprzednio nieopisanych mutacji oraz dwie już wcześniej znane. Po-
twierdzono występowanie trzech znanych polimorfizmów. Większość (7 na 8) nowych mutacji 
miała charakter heterozygotyczny.
W pracy wykazano, że częstotliwość mutacji w analizowanych fragmentach genu PKD1 w po-
pulacji dolnośląskiej jest mniejsza, niż publikowane dane literaturowe dotyczące populacji innych 
obszarów geograficznych. Nie wykryto delecji i insercji, które są często obecne w analizowanych 
wyżej opisanych rejonach genu PKD1. Może być to związane z ograniczoną liczbą analizowa-
nych pacjentów. Uzyskane rezultaty wskazują, że wszystkie odkryte przez nas mutacje w genie 
PKD1 nie wywierają istotnego wpływu na obraz kliniczny choroby.
zwyrodnienie wielotorbielowate · fenotyp · mutacja w genie PKD1 
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IntroductIon
Autosomal dominant polycystic kidney disease (ADPKD) 
is the most common inherited kidney disorder, with an 
incidence of 1 in 400 to 1000 [7]. It is characterized by 
the development and progressive enlargement of cysts in 
the kidney, with end-stage renal disease (ESRD) typically 
occurring in mid-adulthood (between 40 and 75 years of 
age). ADPKD is caused by mutation in one of two genes: 
PKD1 (85% of cases), and PKD2 (15%); the PKD1 gene is 
located on chromosome 16 (position: 16q13.3) and PKD2 
on chromosome 4 (position: 4q21-22) [2,5].
The diagnosis of ADPKD is usually determined by crite-
ria of renal ultrasound imaging of the development and 
number of cysts. However, there are a number of scenarios 
in which clinicians may encounter patients with atypical 
cystic disease in whom the diagnosis may not be obvious. 
In such cases, DNA-based assays for the recognition of 
ADPKD may be required. 
Clinically, mutations in the PKD1 gene indicate more se-
vere disease than PKD2 mutations, with medium ages of 
ESRD development of 54.3 vs. 74 years [7]. Linkage analy-
ses for ADPKD are of limited utility, because of genetic 
heterogeneity as well as the method, which requires the 
participation of more affected family members. Sequencing 
analysis of the PKD1 gene appears challenging, because of 
the large amount of gene duplication, which is designated 
as allele heterogeneity, as well as the fact that most muta-
tions are unique to a single family [7,9]. Genetic hetero-
geneity of PKD1 mutations results in a significant number 
of ADPKD patients without recognized genetic defects. 
The number of mutations in the PKD1 sequence varies 
depending on the particular population and geographic 
region. Various mutations in the PKD1 gene probably have 
different effects on the clinical course of the disease.
The goal of the present study was to evaluate the utility 
and potential relationship between mutations discovered in 
exons 43-44 and 15 of the PKD1 gene in a Lower Silesian 
population and the clinical course of ADPKD.
MaterIals and Methods
Subject selection
Patients were recruited from the Outpatient Nephrology 
Department of the Medical University Hospital in Wroclaw, 
Poland. The study was approved by the Medical Univer-
sity Ethics Committee. The genetic analysis was performed 
among 134 patients from Lower Silesia. The genetic inves-
tigation and complete set of clinical data were available from 
81 patients (46 female and 35 male, mean age: 42.3± 13.1 
years). The control pool consisted of 49 persons.
Clinical examination
The diagnosis of ADPKD was based on clinical history, 
symptoms, and ultrasound analyses. 
DNA isolation
Genomic DNA was extracted from peripheral blood by 
a salting-out procedure using proteinase K [4]. In some 
cases, DNA was additionally purified with a Qiaex II Gel 
Extraction Kit (Qiagen).
Identification of mutations in the PKD1 gene
Polymerase chain reactions (PCRs) were used to amplify 
fragments of the 3’ and 5’ regions of the PKD1 gene.
The 256-bp fragment amplified with primers C1 
(5’CGCCGCTTCACTAGCTTCGAC3’) and C3 
(5’CCAAGGTGACCCCCAGGAG3’) and the 174-
bp fragment, which derived from the previous one, be-
longed to the 3’ PKD1 gene region. In the case of the 
5’ region, a 4.4 kb long-range PCR product, amplified 
by the primers F13 (5’TGGAGGGAGGGACGC-
CAATC3’) and R27 (5’GTCAACGTGGGCCTC-
CAAGT 3’), which covered part of exon 15, served as 
the template for nested PCR to obtain the fragments 
of 568 bp and 417 bp. The 568-bp fragment was am-
plified with primers 568U (5 GGAGGAGGGGCT-
GAGCTGGGAGAC3’) and 568L (5’GACGC-
GGGGGAAGCTGTGGGAGAA3’). The 417-bp 
fragment was amplified with primers 417U (5’AGT-
CACCGCGTCCAACAACATCTC3’) and 417L 
(5’CACCCAGGAATAGCGCACATCACT3’). The 
PCR assays were carried out on a BIOMETRA (Per-
sonal Cycler 3,01 Biotron 1995) thermocycler. The PCR 
mixture (depending on the amplified fragment) con-
tained in a 20-50 ml total volume 20-50 ng of genomic 
DNA (in the case of long-range PCR, the amount of 
DNA was doubled), 0.25 mM of each deoxyribonucle-
otide (dNTP), 0.45 µM of each forward and reverse 
primer (indicated above), 1 x conc. DyNAzyme DNA 
(or 1 x DyNAzyme EXT DNA for the long-range PCR 
assay) polymerase buffer and 0.5-1 unit of DyNAzyme 
DNA (or 2 units of DyNAzyme EXT DNA) polymerase 
(Finnzymes). The thermal profile was as follows: initial 
denaturation at 96°C for 5 min and then 35 cycles (de-
naturation at 94°C for 1 min, annealing at 60-63°C for 
45 s to 1 min, elongation at 72°C for 2-3 min, depend-
ing on the primer pair), and final elongation at 72°C 
for 10 min.
In the case of the 256 bp fragment all patients were first 
screened by heteroduplex analysis then single-stranded 
conformational polymorphism (SSCP), multitemperature 
single-stranded conformational polymorphism (MSSCP), 
and then submitted to sequencing.
PCR products were separated by electrophoresis on 1.5% 
agarose gel and stained with ethidium bromide. After 
subsequent purification (using Gel Out kit, A&A Bio-
technology) according to the manufacturer’s protocol, 
they were bi-directionally sequenced employing the Big 
Dye Tv 3.1 sequencing reaction kit (Applied Biosys-
tems) with the appropriate primer and run on the au-160
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tomatic capillary sequencing system (ABI Prism 31.30 
XL, Applied Biosystems). All sequencing analyses were 
performed at least in 3 biological replicates at the lo-
cal facility (Faculty of Biology, Adam Mickiewicz Uni-
versity in Poznań). For the identification of mutations 
within analyzed fragments of the PKD1 gene, genomic 
and cDNA reference sequences (Ref_Seqs) with acces-
sion numbers NC_000016.9 and NM_001009944.2, 
respectively, were used.
Angiotensin-converting enzyme (ACE) polymorphism 
was determined by the method of Cambien et al. [1] 
with the modification of Zak et al. [14] and verified by 
additional PCR with primers described by Lindpaint-
ner et al. [3].
Statistical analysis
The significance of all clinical parameters as well as their 
correlation with the analyzed genotypes was statistically 
analyzed using the STATISTICA software package v. 
8.00. The ANOVA test, Wilcoxon’s test, chi-squared test, 
Pearson’ correlation, and Spearman’s correlation were ap-
plied where appropriate.
Table 1. PKD1 gene mutations and polymorphic changes identified in the Silesian population
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Refseq (flanking regions 
are also displayed) 
Alterations 
in the mRNA Refseq 
Remarks
77 3’ region, EX42 174 g.44418 T > G
GCG T>G CCG c.11863T > G novel, heterozygous, change in restriction 
sites, aminoacid substitution (p.V3884G)
77
3’ region,
EX43
256
g.44991G > C
CTC G>C CTG c.12188G > C (p.(=))  novel, heterozygous, change in restriction 
sites
116 g.44976T > G
CCG T>G GGC c.12173T > G (p.(=))  novel, heterozygous
118 3’ region,
EX44
g.45092C > A
AGG C>A TGC c.12214C > A novel, heterozygous, change in restriction 
sites, aminoacid substitution (p.A4001N)
47
5’ region,
EX15
568
g.26180C > T
CTT C>T GTG c.5657C > T (p.(=))  novel, heterozygous
47 g.26361G > C
TCA G>C CCA c.5838G > C novel, heterozygous, change in restriction 
sites, aminoacid substitution (p.A1877P)
77 g.26359C > A
TCT C>A AGC c.5836C > A novel, create premature stop codon 
(p.S1876*)
23 g.26456G > A
TCA G>A ATC c.5933G > A (p.(=)) novel, heterozygous, change in restriction 
sites
78 g.26495G > A
CCT G>A CAG c.5972G > A (p.(=))
recurrent, heterozygous, change in 
restriction sites, likely neutral polymorphism 
(PKDB), synonymous (dbSNP)
17 g.26495G > A
CCT G>A CAG c.5972G > A (p.(=))
recurrent, change in restriction sites, likely 
neutral polymorphism (PKDB) , synonymous 
(dbSNP)
17
417
g.25397A > C
TGC A>C AGC c.4874A > C (p.(=))
recurrent, heterozygous, rare 
polymorphism, likely neutral polymorphism 
(PKDB), synonymous (dbSNP)
22  g.25397 A > C
TGC A>C AGC c.4874A > C (p.(=))
recurrent, heterozygous, rare 
polymorphism, likely neutral polymorphism 
(PKDB), synonymous  (dbSNP)
Accession numbers for the genomic and cDNA reference sequences (Refseqs): genomic sequence [GenBank: NC_000016.9]; cDNA sequence [GenBank: NM_001009944.2]161
(Table 1 and 2) other ADPKD patients were also screened 
for mutations and recurrent polymorphisms.
The clinical phenotypes of these patients are shown in Table 2. 
The clinical significance of different PKD1 mutations was 
investigated in 81 persons. Apart from patients shown in 
Table 2, in the remaining group derived from 81 patients, 
8 had severe hypertension, 5 had large and 16 had moderate 
kidney size, and 6 of them represented DD ACE genotype. 
None of them had genetic changes. It has to be added that 2 
members of family no. 16 had not yet shown typical clinical 
ADPKD phenotype. Interestingly, all the analyzed members 
of this family displayed the DD ACE genotype.
The clinical severity of ADPKD was determined based on 
two criteria: the rate of estimated glomerular filtration rate 
(eGFR) decline and the level of the hypertension score. To 
determine eGFR decline rate, the index of clinical sever-
ity (ICS) was calculated according to the formula: (age at 
entry into the study)/eGFR (abbreviated MDRD formula) 
× 10. The severity of hypertension (HS) was scored based 
on the number antihypertensive drugs taken. A score of 1 
was given to patients without hypertension, 2 to persons 
receiving one or two antihypertensive medications, and 3 
to patients treated with three or more drugs.
ACE polymorphism of the analyzed patients (46 women, 
35 men) did not reveal a predominance of the DD geno-
type or correlation with the severity of the disease.
results
In the present study we tried to evaluate whether the 
discovered novel mutations in the PKD1 gene are as-
sociated with the clinical phenotype of the disease. The 
data of all the sequenced fragments were compared with 
the sequences of corresponding fragments of 49 healthy 
persons.
In total, four novel mutations were found in the 3’ PKD1 
region and four in the 5’ region. One mutation (A→C) 
at position 25397 represented recurrent change – ac-
cording to the newest data of the Mayo database [6]. 
Two others at position 26495 are considered as likely 
polymorphisms according to the NCBI/SNP Database 
[10]. However, in our case, this change represents a rare 
polymorphism. We consider three of the polymorphic 
changes detected in the 5’ end of the PKD1 gene re-
gion as rare in the Lower Silesian population; however, 
the Mayo database describes them as polymorphisms 
(Table 1). One mutation (C→A at nucleotide position 
26359) created the stop codon TAA, making polycystin 
1 shorter (Table 1). Five mutations caused changes in 
the restriction site.
It is worth noting that in one family, one member dis-
played three mutations and another displayed two. Apart 
from members of three families displaying mainly all the 
detected novel mutations and known polymorphic changes 
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Table 2. Clinical characterization of patients showing genetic changes
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47N M 41 55 71,6 7.5 severe medium no DD C→T
G→C Myocardial hypertrophy
77N K - 24 82.8 - - - - DD
C→A
T→G
G→C
2 cysts in left kidney
78N M - 19 134.3 - - - - DD G→A Renal colic
10
116N F 43 55 82,7 6.7 moderate medium yes II T→G Leucopenia
118N M 53 61 43,8 13.7 severe normal no DD C→A LA hypertrophy, mitral valve 
insufficiency
15
1N M 40 56 89,3 6.2 moderate medium no ID   Myocardial hypertrophy
21N K - 30 124 - - - - II Cardiac pulse disorder
22N K - 119.3 - ? ? ? DD A→C Kidney stones
- 23N K 20 22 94 2.3 no Middle no II G→A -
- 17N K 37 - - - - - ? DD A→C
G→A Colonic diverticulosis162
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dIscussIon
PKD1 mutations are considered an important factor cau-
sing ADPKD; however, some observations suggest that 
genetic susceptibility might contribute to the varied di-
sease phenotype.
We expected that finding recurrent mutations may have 
diagnostic implications and simplify further molecular ana-
lyses. Indeed, in one case we confirmed the A→C substi-
tution at nucleotide position 25397 of PKD1 as well as 
another, i.e. G→A at position 26495. The latter is consi-
dered as a likely polymorphism [6] (Table 1). Generally, 
we could not detect many genetic abnormalities (deletions 
and insertions), which are often present in these regions 
of the PKD1 gene [9,12]. This may be due to the limited 
number of patients used in the research [9].
The latter seems to be especially important in determining 
the influence of newly discovered mutations and polymor-
phisms on the clinical phenotype. 
The latest data [11,13] concerning mutations in the 5’- and 
3’-end region of PKD1 in Czech and Chinese populations 
showed few novel mutations. In the 3’-end region of the 
PKD1 gene in a Czech population Stekrova et al. showed 
six new mutations, displaying only substitutions [11]. Inte-
restingly, in the Lower Silesian population we also detected 
only substitutions (eight) that were not previously reported. 
Recently, Yu et al. [13] described a mutation that resulted 
in an amino acid substitution at codon 1908 (CAG) of the 
polycystin amino acid sequence. In contrast, in our case in 
the third position of the same codon a silent change oc-
curred only (c.5933G>A). The obtained results confirmed 
that some mutations were present in particular families 
living in a particular geographical region. 
The newly detected mutations were discovered in three 
families (Table 1); this may suggest significant selection 
eliminating mutations [9] or reflect different predisposi-
tions to mutation of the wild allele of PKD1, as well as 
indicating the interaction of modified genes and environ-
mental conditions. A major question arising from this study 
is whether the detected mutations influence the expression 
product of the PKD1 gene. The characteristic feature of the 
detected mutations is that most of them are heterozygous 
(7/8). Recently, Rossetti et al. [8] identified alleles of the 
PKD1 gene with no or incomplete penetration, which may 
cause different severity of disease depending on whether 
they are inherited in the heterozygous or homozygous state 
or in trans with another mutation. This may account for 
the considerable phenotypic variability seen in ADPKD 
families. In the analyzed population, none of the discove-
red changes in the PKD1 gene had any effect on clinical 
phenotype of the disease (i.e. rate of eGFR decline, kidney 
size, hypertension severity). No correlation between ACE 
genotype and disease severity, hypertension, or vascular 
complication was found. All these data support the view 
that genetic defects of the PKD1 gene are extremely hete-
rogeneous and at present it is difficult to discover a direct 
correlation between genetic abnormalities and the clinical 
shape of the disease. It has to be noted that we did not 
perform any PKD2 analysis. 
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